Pharmaceutical

IGI and AbbVie sign licence deal for cancer and autoimmune therapy

IGI Therapeutics has signed an exclusive licensing agreement with AbbVie, for ISB 2001 to treat cancer and autoimmune diseases.

Jul 11, 2025 - 06:00
IGI and AbbVie sign licence deal for cancer and autoimmune therapy
IGI Therapeutics has signed an exclusive licensing agreement with AbbVie, for ISB 2001 to treat cancer and autoimmune diseases.
Read the original article

Tags:

Previous Article

The unsustainability of clinical trials and need for transformative change

Next Article

Modular manufacturing: The key to unlocking mRNA expansion?

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Opko and Entera focus on oral care for obesity and metabolic disorders

Opko and Entera focus on oral care for obesity and meta...

Mar 19, 2025

FDA grants breakthrough status to Grin Therapeutics’ radiprodil

FDA grants breakthrough status to Grin Therapeutics’ ra...

Feb 27, 2025

STAT+: White House moves closer to a ban on menthol cigarettes, amid intensifying opposition from tobacco companies

STAT+: White House moves closer to a ban on menthol cig...

Oct 16, 2023